1. Home
  2. SAVA vs DRIO Comparison

SAVA vs DRIO Comparison

Compare SAVA & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cassava Sciences Inc.

SAVA

Cassava Sciences Inc.

HOLD

Current Price

$2.13

Market Cap

96.1M

Sector

Health Care

ML Signal

HOLD

Logo DarioHealth Corp.

DRIO

DarioHealth Corp.

HOLD

Current Price

$11.01

Market Cap

84.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAVA
DRIO
Founded
1998
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.1M
84.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SAVA
DRIO
Price
$2.13
$11.01
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$5.00
$50.00
AVG Volume (30 Days)
772.9K
18.2K
Earning Date
03-02-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$24,732,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.29
52 Week Low
$1.15
$5.94
52 Week High
$4.98
$17.74

Technical Indicators

Market Signals
Indicator
SAVA
DRIO
Relative Strength Index (RSI) 47.99 49.56
Support Level $2.04 $10.00
Resistance Level $2.22 $11.25
Average True Range (ATR) 0.11 0.70
MACD 0.03 0.07
Stochastic Oscillator 62.86 65.14

Price Performance

Historical Comparison
SAVA
DRIO

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

About DRIO DarioHealth Corp.

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Share on Social Networks: